Instrument Inactif

Communiqués Roche Holding Ltd. Swiss Exchange

Actions

CH0012032048

Temps réel estimé Cboe Europe Autres places de cotation 09:44:02 18/07/2024
277,2 ^CHF	0,00 %

09:04	Le tir groupé sur la Chine assomme la tech
08:45	AVIS D'ANALYSTES DU JOUR : Air Liquide, ASML, Danone, OVH, Air France, Spie, Soitec...

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Genentech’s Vabysmo Showed Extended Durability, Continued Efficacy and a Consistent Safety Profile in Long-Term Diabetic Macular Edema (DME) Study	17/07	BU
Genentech Announces Positive Phase I Results of Its Oral GLP-1 Receptor Agonist CT-996 for the Treatment of People With Obesity	17/07	BU
Genentech to Reintroduce Susvimo for People With Wet Age-related Macular Degeneration (AMD)	08/07	BU
FDA Approves Genentech’s Vabysmo Prefilled Syringe (PFS) for Three Leading Causes of Vision Loss	05/07	BU
Genentech Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Squamous Non-Small Cell Lung Cancer	04/07	BU
Genentech’s Phase III STARGLO Study Demonstrates Columvi Significantly Extends Survival in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma	15/06	BU
Five-year Data for Genentech’s Evrysdi Show the Majority of Treated Children With a Severe Form of Spinal Muscular Atrophy (SMA) Achieved or Maintained the Ability to Sit, Stand or Walk	07/06	BU
FDA Grants Priority Review to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation	29/05	BU
Roche and Hitachi High-Tech extend their long-standing partnership	28/05	AQ
FDA Grants Breakthrough Therapy Designation to Genentech’s Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation	21/05	BU
Genentech Reports Positive Phase Ib Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People With Obesity	16/05	BU
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer	18/04	BU
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS	17/04	BU
Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study	15/04	BU
Invitation to Roche's First Quarter Sales 2024 Presentation	25/03	AQ
Roche showcases new navify® digital solutions that generate operational insights for faster decision-making in diagnostics at HIMSS¹ 2024	12/03	AQ
Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure	06/03	AQ
New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies	25/02	BU
FDA approves Xolair as first and only medicine for children and adults with one or more food allergies	19/02	AQ
FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies	16/02	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

ROCHE HOLDING : L'obésité pourrait être à l'origine de la rédemption de Roche

Le 17 juillet 2024 à 18:26

Obésité : Roche se lance dans la bataille

Le 04 décembre 2023 à 09:45